reported that GRb1 combined with apatinib could inhibit tumor cell glycolysis, reduce tumor cell proliferation and migration, upregulate the immune-related indices CD3+ and CD4+, increase apoptosis, enhance the expression of immune regulatory molecules, and exert synergistic anticancer effects on nasopharyngeal carcinoma cells via ginsenosides to inhibit the malignant progression of nasopharyngeal carcinoma (16). Here, CD4 is linked to neoplasm.